Safety and Bioavailability of IV and SC LBR-101

NCT01991509 ↗

Phase 1 Completed 36 enrolled Teva Branded Pharmaceutical Products R&D, Inc.

RandomizedParallel-groupQuadruple-blindHealth-services research

Summary

The purpose of this study is to assess the safety, tolerability and blood levels of LBR-101 when administered intravenously or subcutaneously to healthy volunteers.

Timeline

Start: 2013-10
Primary completion: 2014-12
Completion: 2015-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fremanezumab	Monoclonal antibody	—	Intravenous

Indications

No indication recorded.